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ABSTRACT
Introduction/aim: Insulin degludec/insulin
aspart (IDegAsp) is a soluble co-formulation of
long-acting and short-acting insulin analogs.
The primary objective of this study was to
investigate the pharmacodynamic response of
once-daily IDegAsp dosing in patients with type
1 diabetes. Pharmacokinetic response, as well as
safety and tolerability, were assessed as
secondary objectives.
Methodology: This was a single-center, open-
label, single-arm study. Twenty-two subjects
received once-daily insulin degludec (IDeg)
(0.42 U/kg) for five consecutive days [with
separate bolus insulin aspart (IAsp) as needed
for safety and glycemic control], to achieve
clinical steady state of the basal component. On
Day 6, they received a single injection of
IDegAsp (0.6 U/kg, comprising 0.42 U/kg IDeg
and 0.18 U/kg IAsp). Pharmacodynamic
response was assessed using a 30-h euglycemic
glucose clamp, with blood glucose stabilized at
a target of 5.5 mmol/L.
Results: The glucose infusion rate profile
showed a rapid onset of action and a distinct
peak due to IAsp, followed by a separate, flat
and stable basal glucose-lowering effect due to
the IDeg component. Modeling data suggested
that the pharmacodynamic profile of IDegAsp
was retained with twice-daily dosing (allowing
for coverage of two main meals daily). IDegAsp
was well tolerated and no safety issues were
identified in this trial.
Conclusions: In conclusion, the IAsp
component of IDegAsp has a fast onset of
appearance and a peak covering the prandial
phase, while the IDeg component has a flat and
an evenly distributed pharmacokinetic profile
over 24 h. IDegAsp is the first co-formulation of
a basal insulin analog with an ultra-long
duration of action and a mealtime insulin
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analog in a single soluble injection. These
properties translate into clinically relevant
benefits, including improved glycemic control
and reduction in hypoglycemia.
Keywords: Insulin degludec/insulin aspart;
Pharmacodynamics; Pharmacokinetics; Steady
state; Type 1 diabetes mellitus
INTRODUCTION
In managing the progressive nature of type 2
diabetes mellitus (T2DM) through insulin
therapy, treatment intensification is often
required. When a basal insulin analog is no
longer enough to maintain glycemic control,
patients mainly follow one of two treatment
options. One of these is the addition of separate
bolus insulin injections (a basal–bolus
approach); however, patients can find this
difficult due to the complexity arising from
the separate titration of two different insulin
formulations [1]. The alternative approach of
switching to premixed insulins [2] shows
superior glycemic control to basal insulin but
is associated with reduced fasting plasma
glucose (FPG) control and, in some studies,
less overall reduction in glycated hemoglobin
(HbA1c), compared to basal–bolus insulin
treatment [3–5].
One reason for these findings may be the
non-optimal pharmacokinetic and
pharmacodynamic characteristics of premixed
formulations, which consistently use
protaminated insulins for the basal insulin
component, resulting in greater variability, a
prolonged glucose-lowering effect beyond the
time required for prandial control, and a shorter
duration of action compared to basal insulin
analogs [6–10]. Until now, it has not been
possible to co-formulate a basal and a short-
acting insulin analog due to interactions
between the two insulins that blunt
absorption, particularly that of the short-
acting insulin [11]. Insulin glargine is soluble
at an acidic pH of 4, which has prevented a co-
formulation with bolus insulins that are soluble
at a neutral pH of 7.4. Similarly, co-formulation
of insulin detemir with rapid-acting insulin
analogs has been shown to result in the
formation of mixed hexamers displaying a
pharmacokinetic/pharmacodynamic profile
unsuitable for optimum glycemic control [11].
Insulin degludec/insulin aspart (IDegAsp) is
a soluble co-formulation of two distinct insulin
analogs in the ratio 70% insulin degludec (IDeg)
to 30% insulin aspart (IAsp) [12]. Figure 1 [13–
15] shows the mechanism of action of IDegAsp
whereby IAsp is rapidly absorbed into the
circulation [16], while IDeg provides stable
coverage of basal insulin needs due to its
flatter and more consistent pharmacodynamic
profile with a duration of action exceeding 42 h
and four times less within-subject variability
compared to insulin glargine [13, 17, 18].
As a result of the [24 h half-life of IDeg, the
pharmacodynamic properties of IDegAsp
should be evaluated at steady state. As patients
with T2DM may retain some beta-cell function,
and may be characterized by high insulin
resistance, patients with type 1 diabetes
mellitus (T1DM) are the preferred population
in which to investigate insulin
pharmacodynamic endpoints. T1DM is
characterized by absolute insulin deficiency as
a result of an autoimmune destruction of
pancreatic b cells [19]. As a consequence,
patients with T1DM are dependent on insulin
replacement therapy. In pharmacological
studies, the insulins used for therapy are
washed off, so that the effect of the study
insulin can be evaluated without influence of
exogenous or endogenous insulin. The main
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objective of the present study was to investigate
the steady-state pharmacodynamic and
pharmacokinetic response of once-daily
IDegAsp in subjects with T1DM who had been




This single-center, single-arm, open-label trial
was registered with clinicaltrials.gov
(NCT01590836), and the protocol was
reviewed and approved by the local health
authority (Bundesinstitut fu¨r Arzneimittel und
Medizinprodukte) in accordance with
regulations, and by the appropriate ethics
committee (A¨rztekammer Nordrhein). All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study. The study was performed in
accordance with Good Clinical Practice as
defined by the International Conference on
Harmonisation. Subjects were fully informed of
the risks of the trial and were made aware that
they could withdraw from the trial at any time
for any reason. Patients were informed verbally
and in writing, and written consent was
obtained before any trial-related procedures
were initiated.
Subjects
Trial participants included 22 men and women
aged 18–65 years, with T1DM, treated with
insulin for at least 12 months with a current
daily basal insulin requirement of C0.2 U/kg/
day and a total insulin dose of \1.2 U/kg/day.
Eligible subjects were also required to have a
body mass index (BMI) in the range of
18.0–28.0 kg/m2, an HbA1c level of B9.5%, and
a fasting C-peptide level of B0.3 nmol/L.
Subjects were excluded from participation if
they had a history or presence of cancer or
Fig. 1 Schematic illustration showing the mechanism of
action of IDegAsp combination insulin. In solution, the
IDeg component forms soluble dihexamers at neutral pH,
whereas IAsp remains as distinct hexamers. Upon subcu-
taneous injection, as illustrated, IDeg dihexamers immedi-
ately self-associate into stable multi-hexamers in the
subcutaneous tissue from which IDeg monomers dissociate
slowly and continuously. By contrast, IAsp hexamers
promptly dissociate to monomers that are rapidly absorbed
into the circulation [13–15]. IAsp, insulin aspart; IDeg,
insulin degludec; IDegAsp, insulin degludec/insulin aspart
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cardiovascular disease, supine blood pressure
beyond the normal range (90–140 mmHg
systolic; 50–90 mmHg diastolic), proliferative
retinopathy or maculopathy and/or severe
neuropathy, recurrent severe hypoglycemia
(more than one episode requiring assistance in
the past 12 months) or hypoglycemia
unawareness, or smoked [5 cigarettes or the
equivalent, per day.
Interventions
The trial consisted of a screening visit (Visit 1),
followed by a treatment period (Visits 2–8), and
a follow-up visit (Visit 9). After screening, all
subjects received IDeg (0.42 U/kg) once daily for
5 days to reach steady state [20]. IAsp was given
as required, which enabled individualization of
bolus doses on Days 1–5 (IAsp has a short
exposure and therefore does not accumulate
over time). On Day 6, subjects received a single
dose of IDegAsp (0.6 U/kg, comprising 0.42 U/
kg IDeg and 0.18 U/kg IAsp). At each dosing
visit, trial product was administered at
approximately 8 p.m. This time was chosen for
convenience in performing the clamp
procedure and does not reflect requirements in
normal clinical practice.
IDeg and IDegAsp were dosed as
subcutaneous injections into a lifted skinfold
of the lower abdominal wall above the inguinal
area. Both were provided in 3 mL Penfill
cartridges (Novo Nordisk, Bagsvaerd, Denmark)
(100 U/mL) and administered using a syringe
and needle.
After administration of IDegAsp on Day 6,
the steady-state pharmacodynamic response
was evaluated using a 30-h euglycemic glucose
clamp performed with a Biostator device (MTB
Medizintechnik, Amstetten, Germany), as
described previously [18]. In brief, 5–6 h before
dosing of the trial product, subjects received a
variable intravenous infusion of human insulin
(15 IU Actrapid, 100 IU/mL in 49 mL saline
and 1 mL of the subject’s blood) or glucose to
obtain a blood glucose clamp target level of
5.5 mmol/L (100 mg/dL). After trial product
administration, when only insulin was infused
to maintain the glucose clamp target, the rate of
insulin infusion was decreased gradually and
stopped completely when blood glucose had
decreased by 0.3 mmol/L (5 mg/dL); glucose
infusion was then initiated to keep the glucose
concentration constant at the glucose clamp
target of 5.5 mmol/L (100 mg/dL). The clamp
continued for 30 h post-dosing of trial product,
but was terminated earlier if the blood glucose
consistently exceeded 13.9 mmol/L (250 mg/
dL) without any glucose having been
administered for at least 30 min. During the
entire clamp procedure, subjects remained
fasting (with no oral intake other than water)
and stayed in a supine or semi-supine position.
The glucose infusion rate (GIR) required to
keep the blood glucose concentration at the
target level was recorded every minute
throughout the euglycemic clamp.
Approximately every 30 min throughout the
glucose clamp, blood glucose measurements
from the Biostator were checked against blood
glucose measurements performed by a glucose
analyzer (Super GL Glucose Analyzer, Hitado,
Mo¨hnesee, Germany). Blood samples for
determination of serum IAsp concentration
were taken on Day 6 at the following times:
5 min predose, 0 min, at 10 min intervals until
2 h post-dose, then every 15 min to 3 h, then at
3, 4, 5, 6, 8, 10, 11 and 12 h post-dose. Serum
IDeg concentrations were measured in blood
samples taken 5 min predose and at 0 min on
Days 1–5 then on Day 6, at 5 min predose,
0 min, 30 min, 1 h and thereafter every hour
until 16 h, then at 18, 20, 22, 24, 30, 36 and
48 h.
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Each subject remained in the clinic for 48 h
after IDegAsp dosing. Subjects returned to the
clinic at time points 72, 96 and 120 h after
dosing to have blood samples taken for
pharmacokinetic assessment of IDeg and for
monitoring of blood glucose.
Serum IAsp concentrations were quantified
using a validated IAsp-specific enzyme-linked
immunosorbent assay (ELISA). Serum IDeg
concentrations were measured using a
validated IDeg-specific sandwich ELISA.
Assessments
The primary endpoint was the total glucose-
lowering effect estimated by the area under the
GIR curve during one 24-h dosing interval at
steady state (AUCGIR,s,SS) after administration of
IDegAsp.
Secondary endpoints included time to
GIRmax,SS (tGIRmax,SS), duration of action of
IDegAsp, total exposure of IDeg (AUCIDeg,s,SS)
and distribution of IDeg exposure over the 24-h
dosing interval at steady state (AUCIDeg,0–12h,SS/
AUCIDeg,s,SS), total exposure of IAsp
(AUCIAsp,0–12h), and time to maximum
observed serum concentration of IAsp
(tmax,IAsp). In addition, using the data obtained
from once-daily dosing in this trial, a
pharmacokinetic/pharmacodynamic model
was used to simulate steady-state GIR response
following twice-daily dosing of IDegAsp.
Safety was monitored for both IDeg and
IDegAsp administration. Safety endpoints
included treatment-emergent adverse events,
confirmed hypoglycemic episodes, physical
examination, vital signs, electrocardiogram
(ECG), and clinical laboratory values.
Confirmed hypoglycemia was defined as any
episode of severe hypoglycemia (as per the
American Diabetes Association definition [21])
or minor hypoglycemia [plasma glucose
\3.1 mmol/L (56 mg/dL) or blood glucose
\2.8 mmol/L (50 mg/dL)].
Statistical Methods
Pharmacokinetic and pharmacodynamic
analyses were based on the full analysis set,
which included 22 subjects. The primary
endpoint, AUCGIR,s,SS, was derived from
individual GIR profiles and calculated as the
area under the smoothed GIR profile using the
linear trapezoidal technique on interpolated
data points.
Secondary pharmacodynamic endpoints
were derived from individual GIR profiles
(smoothed) and blood glucose profiles at
steady state. Duration of action was calculated
as the time from administration of IDegAsp
until blood glucose concentration was
consistently [8.3 mmol/L (end of action)
during the euglycemic glucose clamp at steady
state [22]. Statistical analyses were performed
using SAS 9.1.3 software (SAS Institute Inc.,
Cary, NC, USA).
The pharmacokinetic/pharmacodynamic
model used to simulate steady-state GIR
response consisted of separate pharmacokinetic
and pharmacodynamic components for IDeg
and for IAsp. For IDeg, the pharmacokinetic
component was based on absorption (with a
depot compartment and a transit compartment,
an absorption-rate parameter and a transit-rate
parameter), and disposition (with a single
distribution compartment, a clearance
parameter, and a volume-of-distribution
parameter), and the pharmacodynamic
component linked the concentration in the
distribution compartment to GIR by means of
an insulin-action compartment, a turnover
parameter, and an insulin-sensitivity parameter.
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For IAsp, the pharmacokinetic component was
based on absorption (with a depot
compartment and four transit compartments,
an absorption-rate parameter, and a transit-rate
parameter), and disposition (with a single
distribution compartment, a clearance
parameter, and a volume-of-distribution
parameter), and the pharmacodynamic
component linked the concentration in the
distribution compartment to GIR by means of
an insulin-action compartment, a turnover
parameter, and an insulin-sensitivity
parameter. The GIR contributions for IDeg and
IAsp were subsequently added to simulate total
GIR effect. The parameters of the model were
estimated in a population pharmacokinetic/
pharmacodynamic setting, using a nonlinear
mixed-effects approach, which allowed
individual sets of parameters to be obtained
for each of the subjects included in the trial.
Using the estimated individual parameters, a
simulation of twice-daily multiple dosing was
conducted to obtain a mean steady-state
profile. Twice-daily multiple dosing for 6 days
at a dose level of 0.3 U/kg was simulated for
each of the subjects, and the mean of the
profiles on Day 6 was subsequently calculated.
A dose of 0.3 U/kg was used for the simulation
based on the assumption that the once-daily
dose of 0.6 U/kg would be divided into two for
the twice-daily dose. The modeling was
performed using NONMEM version 7.1.2
(ICON Development Solutions, Ellicott City,
MD, USA) and the corresponding figure was
produced using S-Plus version 8.2 (TIBCO, Palo
Alto, CA, USA).
Safety analyses were based on the safety
analysis set (all subjects who received C1
dose of either IDeg or IDegAsp). Safety




Of the 25 subjects screened, a total of 22
subjects (18 men, 4 women) with T1DM were
exposed to IDeg and IDegAsp during the trial.
No subjects withdrew from the trial. The mean
age of the subjects was 40 years (range
20–56 years), mean HbA1c was 7.9% (range
5.8–9.0%), mean duration of diabetes was
23.1 years (range 8.9–42.9 years), and mean
BMI was 24.6 kg/m2 (range 20.2–27.9 kg/m2)
(Table 1).
Pharmacodynamics
The mean GIR profile at steady state is shown in
Fig. 2, reflecting the primary endpoint,
AUCGIR,s,SS [geometric mean (coefficient of
variation): 3,859 mg/kg (33%)]. The profile
showed a rapid onset of action and a distinct
peak due to the IAsp component, and a
separate, stable basal glucose-lowering effect
Table 1 Subject characteristics
Characteristic Mean (min, max)
Mean age, years 40.0 (20.0, 56.0)






Duration of diabetes, years 23.1 (8.9, 42.9)
HbA1c, % 7.9 (5.8, 9.0)
Fasting C-peptide, nmol/L 0.02 (0.02, 0.08)
BMI, body mass index; HbA1c, glycated hemoglobin
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attributable to the IDeg component. The
median tGIRmax,SS for IDegAsp was 2.5 h. The
clamp was performed when steady state of the
basal component had been established. The GIR
was already elevated at the time of injection of
IDegAsp, owing to the duration of action of
IDeg being [42 h [13], so that the effect of the
previous IDeg injections on Days 1–5 was
expected to elicit a GIR response already at
time-point 0 on Day 6.
Mean blood glucose levels remained at the
clamp target level throughout the euglycemic
clamp procedure (Fig. 3). No subject experienced
end of action (defined as a blood glucose level
[8.3 mmol/L) or early termination during the
30-h clamp, hence the duration of action of
IDegAsp extended beyond 30 h in all 22 subjects.
The model simulating the pharmacodynamic
response to twice-daily dosing of IDegAsp at
steady state indicated that the distinct peak
(due to IAsp) and the separate, flat basal action
(due to IDeg) were retained following each dose
(Fig. 4).
Pharmacokinetics
Mean total serum exposure of IAsp in IDegAsp
(AUCIAsp,0–12h) was 1,087 pmol h/L. The IAsp
component of IDegAsp had a rapid onset of
appearance; tmax,IAsp was 80 min (median). The
mean total serum exposure of IDeg in IDegAsp
(AUCIDeg,s,SS) at steady state, during one dosing
interval, was 72,084 pmol h/L. Exposure to the
IDeg component of IDegAsp was similar in
the first and second 12 h periods. The mean
ratio of AUCIDeg,0–12h,SS/AUCIDeg,s,SS was 0.51,
indicating that IDeg has an evenly distributed
pharmacokinetic profile over 24 h at steady
state. Clinical steady state was achieved after
2–3 days of once-daily IDeg dosing.
Safety
During 5 days of IDeg administration, one
adverse event was reported that was considered
Fig. 2 Mean glucose infusion rate proﬁle of once-daily
insulin degludec/insulin aspart (IDegAsp) administered at
steady state in subjects with type 1 diabetes. OD, once daily
Fig. 3 30-h individual and mean (black line) blood glucose
proﬁles—insulin degludec/insulin aspart (IDegAsp) at
steady state
Fig. 4 Simulated mean glucose infusion rate proﬁle of
insulin degludec/insulin aspart (IDegAsp) administered
twice daily at steady state in subjects with type 1 diabetes.
BID, twice daily
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possibly related to IDeg treatment—a case of
mild headache. Furthermore, while IDeg steady
state was being attained, there were 22 confirmed
hypoglycemic episodes in 13 subjects.
After administration of IDegAsp on Day 6,
there were no reported AEs that were considered
to be related to IDegAsp. A total of six
confirmed hypoglycemic episodes were
recorded in five subjects after administration
of IDegAsp on Day 6. Four occurred 30–48 h
after IDegAsp administration, and the other two
occurred 96–120 h after IDegAsp
administration. These hypoglycemic episodes
may therefore have been related to the
administration of bolus insulin or the switch
to other regimens following cessation of
IDegAsp treatment.
There were no significant treatment-
emergent changes in clinical laboratory
parameters, vital signs, physical examination
or ECG findings following subcutaneous IDeg
and IDegAsp administration. No injection site
reactions were reported during the trial.
DISCUSSION
At steady state, the glucose-lowering effects of
the prandial and basal components of IDegAsp
were distinct and clearly separated. The IAsp
component resulted in a rapid onset of action
and a peak glucose-lowering effect covering the
prandial phase, providing mealtime insulin
control. This was followed by a stable, flat and
ultra-long glucose-lowering effect due to IDeg
that was maintained for [30 h in all trial
subjects. These properties were consistent with
those observed for the individual components
[16, 23].
Historically, it has proven difficult to
combine two different insulin analogs in one
co-formulation, largely owing to interactions
between them that blunt absorption, especially
of the short-acting insulin [11]. In contrast, our
findings show that IDegAsp has a distinct peak
action (IAsp) followed by a separate stable and
sustained basal effect (IDeg). This is reflective of
the distinct mode of action of IDegAsp (see
Fig. 1).
In the present study, the pharmacodynamic
evaluation of IDegAsp was conducted at steady
state due to the ultra-long duration of action of
IDeg. As a result of this duration of action,
metabolic action from the previous IDeg
injection was still in effect when IDegAsp was
injected (the mean GIR at time-point 0 was
around 2 mg/kg/min as indicated in Fig. 2). In
addition, no early termination of the 30-h clamp
was required by any study subject and the
duration of action exceeded 30 h in all patients.
IDeg is indicated for once-daily dosing,
whereas IDegAsp may be administered once or
twice daily with the main meal(s) according to
patient needs and preferences [12, 24]. Based on
simulated steady-state pharmacodynamic
modeling, dividing the IDegAsp dose in two
(0.3 U/kg twice-daily [BID]) gives the same basal
glucose-lowering effect as once-daily dosing,
due to the fact that the concentration of the
basal part of IDegAsp, IDeg, remains unchanged
(provided the total daily insulin dose is the
same). Thus, at steady state, the basal glucose-
lowering effect is only dependent on dose and
not on dosing frequency. In contrast, the bolus
peak associated with the IAsp component of
IDegAsp will be half the size when switched
from once-daily to twice-daily dosing. This dose
schedule would provide insulin coverage for
two main meals, which as the disease progresses
is often required due to increasing
hyperglycemia on basal-only therapy [25, 26].
Overall, the data from this study suggest that
IDegAsp could provide flat and stable basal
insulin coverage (provided by IDeg at steady-
262 Diabetes Ther (2014) 5:255–265
state conditions) and bolus mealtime insulin
control with reduced injection burden
compared to standard basal and bolus therapy.
The preservation of these distinct glucose-
lowering effects in the IDegAsp combination
indicates potential improvements in FPG and
reductions in hypoglycemia compared to
premixed insulins. A meta-analysis of two
recent phase 3 trials [27, 28] in patients with
T2D comparing twice-daily IDegAsp to the
premixed insulin preparation, BIAsp 30 (70%
IAsp protamine suspension; 30% IAsp) indicates
that these pharmacodynamic properties
translate into meaningful clinical benefits.
IDegAsp showed superior reductions in FPG,
comparable HbA1c and reduced daily insulin
dose at end of trial compared with BIAsp 30
[29]. Furthermore, rates of overall confirmed
hypoglycemia and nocturnal confirmed
hypoglycemia were both significantly lower
with IDegAsp [29].
The current study was not powered to assess
safety and tolerability. However, among the 22
patients enrolled, IDegAsp was well tolerated,
there were no injection site reactions and no
unexpected safety issues were identified.
The main limitation of this study was its
uncontrolled design. Additional potential
limitations include that some study subjects
had a BMI in the overweight range ([25 kg/m2),
and hence may have been characterized as
having impaired insulin sensitivity. Finally,
women were relatively under-represented
among the study participants. A controlled
study has been performed under single-dose
conditions, showing that the 24-h AUCGIR and
GIRmax increased significantly and
proportionally as IDegAsp dose increased [30].
The aim of the present study was to examine the
IDegAsp profile under steady-state conditions.
The GIR profiles from the single-dose study [30]
and the current study at steady state (Fig. 2)
displayed the same shape, although, as expected,
the baseline level was higher at steady state
compared to the single-dose profile.
In conclusion, IDegAsp is the first soluble
insulin combination to offer ultra-long basal
insulin analog coverage in combination with a
well-established mealtime insulin analog in a
single injection. The clinical pharmacokinetic
and pharmacodynamic findings from the
present work have translated into comparable
glycemic control, improved FPG, and
significantly lower levels of hypoglycemia vs
BIAsp 30 in phase 3 clinical trials [27–29].
IDegAsp may therefore represent a clinical
advance in the management of diabetes by
combining a convenient treatment regimen
with reduced hypoglycemia compared to
existing treatment options.
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